Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Binacea Pharma General Information
Currently conducting a Phase 1 dose escalation study (NCT05150457) to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BNA035 in patients with advanced solid tumors. The study aims to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D).
Contact Information
Primary Industry
Biotech
Corporate Office
Hayward, California
United States
United States
Drug Pipeline
HLX35
INDKey Partnerships
Henlius Biotech (licensed HLX35, an anti-EGFR and anti-4-1BB bispecific antibody)
Binacea Pharma Funding
No funding data available
To view Binacea Pharma's complete valuation and funding history, request access »